July 28 is World Hepatitis Day. In 2016, every country in the world signed up to eliminate viral hepatitis by 2030 and World Hepatitis Day is an annual reminder to continue that fight. Viral hepatitis (most notably hepatitis A, B, and C) kills an estimated 1.4 million people every year around the world, but these deaths are preventable with early detection.
In the United States, viral hepatitis affects millions of people, with hepatitis C affecting the largest population – about 40,000 new cases of acute hepatitis C every year. An estimated 2.4 million people in the United States are living with chronic hepatitis C, which occurs if acute hepatitis C infection is left untreated.
PathGroup offers many testing options to help healthcare providers diagnose viral hepatitis in their patients. Visit http://www.pathgroup.com/clinical/testing-menu/ for a full list of testing options.
Reported cases of vector-borne diseases – diseases contracted from mosquito or tick bites – have tripled since the early 2000s.
Depending on the patient’s geographic location or recent travel destinations, they could be at risk of contracting diseases from ticks and mosquitos.
To learn more, click here.
May 25 is World Thyroid Day. Thyroid disorders affect an estimated 20 million people in the United States – that’s more than 12% of the U.S. population. Thyroid disorders like hyperthyroidism, hypothyroidism, Graves disease, and even thyroid cancer are caused by abnormal activity in the thyroid that can be detected using laboratory testing. PathGroup offers tests that assist healthcare providers in diagnosing thyroid disorders in their patients. To learn more about these testing options, visit the online Directory of Services.
NASHVILLE, May 1, 2019 — PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced that it has acquired Pathologists Bio-Medical Laboratories (PBM), a leading provider of pathology services based in Dallas.
Click here to read the press release.
Sexually transmitted infections (STIs) are viruses or bacteria spread through sexual contact with an infected individual. Some of the most common STIs are: chlamydia, gonorrhea, trichomonas vaginalis, and mycoplasma genitalium (M. gen). An estimated 20 million new STIs occur every year in the United States.
To learn more, click here.
Colorectal cancer is the third most common cancer in the United States. There are an estimated 140,000 new cases diagnosed every year and about 50,000 people lose their lives to colorectal cancer each year. According to the American Cancer Society, the risk of developing colorectal cancer is slightly lower in women (4.15%) than in men (4.49%).
Click here for more information about Colorectal Cancer Awareness Month.
PathGroup recognizes the efforts of the American Heart Association and healthcare providers in identifying, diagnosing and managing patients at risk for and impacted by heart disease.
Click here for more information about American Heart Month.
BALTIMORE – (Monday, January 7, 2019) – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and PathGroup, a premier provider of anatomic, clinical and molecular laboratory services, announced today that they have entered into a co-development agreement for the PGDx elio™ tissue complete assay.
Click Here to read the press release.
Brentwood, TN – (Monday, November 12, 2018) Dr. Kathryn Knight, Medical Director for Women’s Health Services and Cytopathology for PathGroup Laboratories, was elected Speaker of the House of Delegates at the recent annual meeting of the College of American Pathologists in Chicago, Illinois.
Click here to read the entire press release.
After serving as President-Elect/Scientific Program Chair for the annual meeting held in Denver, CO in 2017, Alan Lennon, PhD, FACMG took the helm as President of the Cancer Genomics Consortium. The Cancer Genomics Consortium (CGC) is a non-profit organization formed in 2009 by a group of clinical cytogeneticists, molecular geneticists, and molecular pathologists who are interested in applying whole genome and other genetic technologies to cancer diagnosis and cancer research. During his presidential term, working groups which Lennon fostered back in 2016 to publish evidence-based reviews on assessing whole genome copy number aberrations and copy neutral loss of heterozygosity as best practice in a variety of cancers saw several works accepted for publication. Over 270 cancer geneticists from 7 countries converged on the annual meeting in Nashville, TN, August 5 – 8. The 2018 Annual Meeting was the largest meeting to date and was supported by the largest corporate sponsorship to date. Lennon’s presidential term culminated at the annual meeting, although he serves two more years on the Board of Directors.